Day 3 at the 2017 annual meeting of the American Society of Clinical Oncology touched on immunotherapy combinations and the promise of several novel immunotherapies, including anti-IDO1 checkpoint blockade and a personalized, patient-specific vaccine. Other measures of immunotherapy’s effectiveness, such as patient quality of life, were also discussed. Below are some of the most important findings that were revealed today:
Multiple Tumor Types:
Head and Neck Cancer:
Melanoma / Skin Cancers:
Stomach & Gastrointestinal Cancer:
ASCO17: Day 1 Immunotherapy Highlights
Read Previous Article
ASCO17: Day 3 Immunotherapy Highlights
Read Next Article
*Immunotherapy results may vary from patient to patient.
Cancer Research Institute | National Headquarters
29 Broadway, Floor 4 | New York, NY 10006-3111
Let’s stream for a cause. Make time spent watching your favorite movies and TV shows meaningful.
This July for Sarcoma Awareness Month, we look at new research, new treatments, and how we’re working toward a future immune to sarcoma.